Literature DB >> 21822309

Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL.

A E Sayan1, R Stanford, R Vickery, E Grigorenko, J Diesch, K Kulbicki, R Edwards, R Pal, P Greaves, I Jariel-Encontre, M Piechaczyk, M Kriajevska, J K Mellon, A S Dhillon, E Tulchinsky.   

Abstract

Fos-related antigen 1 (Fra-1) is a Fos family member overexpressed in several types of human cancers. Here, we report that Fra-1 is highly expressed in the muscle-invasive form of the carcinoma of the bladder (80%) and to a lesser extent in superficial bladder cancer (42%). We demonstrate that in this type of cancer Fra-1 is regulated via a C-terminal instability signal and C-terminal phosphorylation. We show that manipulation of Fra-1 expression levels in bladder cancer cell lines affects cell morphology, motility and proliferation. The gene coding for AXL tyrosine kinase is directly upregulated by Fra-1 in bladder cancer and in other cell lines. Importantly, our data demonstrate that AXL mediates the effect of Fra-1 on tumour cell motility but not on cell proliferation. We suggest that AXL may represent an attractive therapeutic target in cancers expressing high Fra-1 levels.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21822309     DOI: 10.1038/onc.2011.336

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

1.  The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells.

Authors:  K Belguise; S Milord; F Galtier; G Moquet-Torcy; M Piechaczyk; D Chalbos
Journal:  Oncogene       Date:  2012-01-30       Impact factor: 9.867

Review 2.  Expression and function of FRA1 protein in tumors.

Authors:  Xiaoyan Jiang; Hui Xie; Yingyu Dou; Jing Yuan; Da Zeng; Songshu Xiao
Journal:  Mol Biol Rep       Date:  2019-10-14       Impact factor: 2.316

Review 3.  TYRO3: A potential therapeutic target in cancer.

Authors:  Pei-Ling Hsu; Jonathan Jou; Shaw-Jenq Tsai
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-02

4.  Notch3 negatively regulates chemoresistance in breast cancers.

Authors:  Xiaoting Gu; Chunxiao Lu; Dongxu He; Yangfan Lu; Jian Jin; Dequan Liu; Xin Ma
Journal:  Tumour Biol       Date:  2016-10-14

5.  Epstein-Barr virus latent membrane protein 2A promotes invasion of nasopharyngeal carcinoma cells through ERK/Fra-1-mediated induction of matrix metalloproteinase 9.

Authors:  Yu-Yan Lan; Jenn-Ren Hsiao; Kung-Chao Chang; Jeffrey Shu-Ming Chang; Chaio-Wei Chen; Hsiao-Ching Lai; Shih-Yi Wu; Tzu-Hao Yeh; Fang-Hsin Chang; Wei-Hung Lin; Ih-Jen Su; Yao Chang
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

6.  Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

Authors:  Judith Müller; Oscar Krijgsman; Jennifer Tsoi; Lidia Robert; Willy Hugo; Chunying Song; Xiangju Kong; Patricia A Possik; Paulien D M Cornelissen-Steijger; Marnix H Geukes Foppen; Kristel Kemper; Colin R Goding; Ultan McDermott; Christian Blank; John Haanen; Thomas G Graeber; Antoni Ribas; Roger S Lo; Daniel S Peeper
Journal:  Nat Commun       Date:  2014-12-15       Impact factor: 14.919

7.  Prostaglandin E₂ induces oncostatin M expression in human chronic wound macrophages through Axl receptor tyrosine kinase pathway.

Authors:  Kasturi Ganesh; Amitava Das; Ryan Dickerson; Savita Khanna; Narasimham L Parinandi; Gayle M Gordillo; Chandan K Sen; Sashwati Roy
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

8.  MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL.

Authors:  Kathryn A Tworkoski; James T Platt; Antonella Bacchiocchi; Marcus Bosenberg; Titus J Boggon; David F Stern
Journal:  Pigment Cell Melanoma Res       Date:  2013-05-21       Impact factor: 4.693

9.  Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis.

Authors:  Christophe J Desmet; Tristan Gallenne; Alexandre Prieur; Fabien Reyal; Nils L Visser; Ben S Wittner; Marjon A Smit; Thomas R Geiger; Jamila Laoukili; Sedef Iskit; Boris Rodenko; Wilbert Zwart; Bastiaan Evers; Hugo Horlings; Abderrahrim Ajouaou; John Zevenhoven; Martin van Vliet; Sridhar Ramaswamy; Lodewyk F A Wessels; Daniel S Peeper
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-12       Impact factor: 11.205

Review 10.  Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy.

Authors:  Maurizio Scaltriti; Moshe Elkabets; José Baselga
Journal:  Clin Cancer Res       Date:  2016-01-13       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.